Weight-loss drug plus IUD aims to save uterus in women at cancer risk
NCT ID NCT05829460
First seen Jan 12, 2026 · Last updated May 09, 2026 · Updated 14 times
Summary
This study was designed to see if combining a weight-loss drug (semaglutide) with a hormone-releasing IUD could help premenopausal women with obesity and a precancerous uterine condition keep their uterus and avoid cancer. It planned to enroll women who wanted to preserve their fertility. However, the study was withdrawn before any participants were enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL HYPERPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.